Execution Version
AMENDMENT NO. 2 TO CREDIT AGREEMENT AND
GUARANTY
This AMENDMENT NO.
2 TO CREDIT AGREEMENT AND GUARANTY, dated as of December 8, 2020 (this “Amendment”), is among ADMA
Biologics, Inc., a Delaware corporation (the “Borrower”), the Lenders party hereto (the “Lenders”),
Perceptive Credit Holdings II, LP, a Delaware limited partnership, as administrative agent (in such capacity, together with its
successors and assigns, “Administrative Agent”). Reference is made to the Credit Agreement and Guaranty,
dated as of February 11, 2019 (as amended by Amendment No. 1 to Credit Agreement and Guaranty, dated as of May 3, 2019, and as
subsequently amended or otherwise modified, the “Credit Agreement”), among the Borrower, the Guarantors
party thereto, the Lenders party thereto and the Administrative Agent. Capitalized terms used herein without definition shall have
the same meanings as set forth in the Credit Agreement, as amended by this Amendment.
RECITALS
WHEREAS, the
Borrower has requested that the Lenders and the Administrative Agent amend the Credit Agreement in order to, among other things,
(i) extend the Maturity Date for the Loans, and (ii) provide an additional tranche of senior, secured, delayed-draw term loans
in an aggregate principal amount of $15,000,000; and
WHEREAS, subject
to the terms and conditions hereof, the Lenders party hereto and the Administrative Agent are willing to agree to such amendments
and other modifications set forth herein.
NOW, THEREFORE,
in consideration of the premises and the agreements, provisions and covenants herein contained, the parties hereto agree as follows:
SECTION
1. AMENDMENTS.
A.
Each of the following definitions in Section 1.01 of the Credit Agreement is hereby amended and restated in its entirety
as follows:
“Borrowing”
means, as the context may require, (i) the borrowing of the Initial Loan on the Closing Date, (ii) the borrowing of the Delayed
Draw Loan on the Delayed Draw Date, (iii) the borrowing of the Tranche 3 Loan on the Tranche 3 Borrowing Date, or (iv) the
borrowing of the Tranche 4 Loan on the Tranche 4 Borrowing Date.
“Borrowing
Date” means, as the context may require, (i) with respect to the Initial Loan, the Closing Date, (ii) with respect
to the Delayed Draw Loan, the Delayed Draw Date, (iii) with respect to the Tranche 3 Loan, the Tranche 3 Borrowing Date, and
(iv) with respect to the Tranche 4 Loan, the Tranche 4 Borrowing Date.
“Commitment”
means, with respect to each Lender, the obligation of such Lender to make Loans to the Borrower in accordance with the terms and
conditions of this Agreement, which commitment is in the amount set forth opposite such Lender’s name on Schedule 1
under the caption “Commitment”, as such Schedule may be amended from time to time pursuant to an Assignment and Assumption
or otherwise. The aggregate Commitment amount (cumulative since the Closing Date) on the Amendment No. 2 Effective Date equals
$100,000,000.
“Loan
Documents” means, collectively, this Agreement, the Notes, the Security Documents, each Borrower Warrant, the Fee
Letter, any Guarantee Assumption Agreement, the Intercompany Subordination Agreement, the Intercreditor Agreement and any other
subordination agreement, intercreditor agreement or other present or future document, instrument, agreement, certificate or other
amendment, waiver or modification of a Loan Document delivered to the Administrative Agent or any Lender in connection with this
Agreement or any of the other Loan Documents, in each case, as amended or otherwise modified.
“Maturity Date”
means the earliest to occur of (x) March 1, 2024 and (y) the acceleration of the Obligations pursuant to Section 11.02.
“Prepayment Premium”
means with respect to any prepayment of any outstanding principal amount of the Loans pursuant to Section 3.03(a) or (b)
occurring (i) on or prior to December 31, 2021, an amount equal to five percent (5.0%) of the aggregate outstanding principal amount
of the Loans being prepaid; (ii) at any time after December 31, 2021 and on or prior to December 31, 2022, an amount equal to two
percent (2.0%) of the aggregate outstanding principal amount of the Loans being prepaid; (iii) at any time after December 31, 2022
and on or prior to December 31, 2023, an amount equal to four percent (4.0%) of the aggregate outstanding principal amount of the
Loans being prepaid; and (iv) at any time thereafter and prior to the Maturity Date, an amount equal to five percent (5.0%) of
the aggregate outstanding principal amount of the Loans being prepaid.
“Warrant
Obligations” means all Obligations of Borrower arising out of, under or in connection with the Borrower Warrants.
B.
The following new definitions are added to Section 1.01 of the Credit Agreement in appropriate alphabetical order:
“Amendment
No. 2” means Amendment No. 2 to Credit Agreement and Guaranty, dated as of December 8, 2020, among the Borrower,
the Lenders party thereto and the Administrative Agent.
“Amendment
No. 2 Effective Date” means December 8, 2020.
“Biotest
Indebtedness” means indebtedness arising under that certain Subordinated Loan Agreement, dated as of June 6, 2017,
by and between Biotest AG (as assignee of Biotest Pharmaceuticals Corporation), ADMA Biomanufacturing, LLC and the Borrower, as
amended from time to time.
“Borrower
Warrants” means, collectively, the Warrant, the Tranche 3 Warrant, the Tranche 4 Warrant, and any other warrants
exercisable into Equity Interests of the Borrower delivered pursuant to or in connection with this agreement, and any replacements,
substitutions, or similar modifications or amendments thereto.
“Tranche 4
Borrowing Date Certificate” has the meaning set forth in Section 6.04(c).
“Tranche
4 Borrowing Date” means the Business Day on which the Tranche 4 Loan is made hereunder, which shall be (x) no sooner
than the date on which each of the conditions precedent set forth in Section 6.04 shall have been satisfied and (y) no later
than December 31, 2020.
“Tranche 4
Loan” means the term loan made by the Lenders on the Tranche 4 Borrowing Date in an aggregate principal amount not
to exceed $15,000,000.
“Tranche
4 Warrant” means that certain Borrower Warrant, dated as of December 8, 2020 and delivered pursuant to Section
6.04(e), as amended, replaced or otherwise modified pursuant to the terms thereof.
C.
Section 2.01 of the Credit Agreement is hereby amended by (1) re-designating clauses (d) and (e) as clauses (e) and
(f), respectively, and (2) adding a new clause (d) to read as follows:
(c) On
the terms and subject to the conditions of this Agreement, the Lenders agree to make the Tranche 4 Loan to the Borrower in
a single Borrowing on the Tranche 4 Borrowing Date, in a principal amount equal to such Lender’s Proportionate Share of $15,000,000;
provided that, after the Tranche 4 Borrowing Date, each Lender’s Commitment with respect to the Tranche 4 Loan shall
automatically terminate.
D.
Section 2.02 of the Credit Agreement is hereby amended and restated in its entirety as follows:
Borrowing
Procedures. The Borrower shall deliver to the Administrative Agent an irrevocable Borrowing Notice (x) for the Borrowing of
the Initial Loan, at least three (3) (but not more than five (5)) Business Days prior to the Closing Date and (y) for the Borrowing
of any of the Delayed Draw Loan, the Tranche 3 Loan or the Tranche 4 Loan, at least five (5) Business Days prior to the proposed
Borrowing Date therefor (which notice, if received by the Administrative Agent on a day that is not a Business Day or after 10:00
A.M. (Eastern time) on a Business Day, shall be deemed to have been delivered on the next Business Day).
E.
Section 3.02(c) of the Credit Agreement is hereby amended and restated in its entirety as follows:
Interest Payment Dates. Accrued
interest on the Loans shall be payable in cash, in arrears, on each Payment Date, and upon the payment or prepayment of the Loans
(on the principal amount being so paid or prepaid); provided that interest payable at the Default Rate, or any accrued interest
not paid on or before the Maturity Date, shall also be payable from time to time on demand by the Administrative Agent until paid
in full in cash.
F.
Section 6 of the Credit Agreement is hereby amended by adding a new Section 6.04 to read as follows:
6.04 Conditions
to the Borrowing of the Tranche 4 Loan. The obligation of each Lender to make its Tranche 4 Loan on the Tranche 4 Borrowing
Date shall be subject to the (i) prior making of each of the Initial Loan on the Closing Date, the Delayed Draw Loan on the Delayed
Draw Date and the Tranche 3 Loan on the Tranche 3 Borrowing Date, (ii) the delivery of a Borrowing Notice as required pursuant
to Section 2.02(a), and (iii) the prior or concurrent satisfaction of each of the conditions precedent set forth below
in this Section 6.04.
(a) Secretary’s
Certificate, Etc. The Administrative Agent shall have received from each Obligor (x) a copy of a good standing certificate,
dated a date reasonably close to the Tranche 4 Borrowing Date, for each such Person and (y) a certificate, dated as of the
Tranche 4 Borrowing Date, duly executed and delivered by such Person’s secretary or assistant secretary, managing member,
general partner or equivalent, as to:
(i) resolutions
of each such Person’s Board then in full force and effect authorizing the execution, delivery and performance of each Loan
Document to be executed by such Person and the Transactions (or confirming that the resolutions executed on the Tranche 3 Borrowing
Date remain in effect);
(ii) the
incumbency and signatures of each Responsible Officer authorized to execute and deliver each Loan Document to be executed by such
Person (or confirming that the incumbency and signatures executed on the Tranche 3 Borrowing Date remain in effect); and
(iii) the
full force and validity of each Organic Document of such Person and copies thereof (or confirming that the Organic Documents certified
to as of the Tranche 3 Borrowing Date remain in effect);
upon which certificates shall be
in form and substance reasonably satisfactory to the Administrative Agent and upon which the Administrative Agent and the Lenders
may conclusively rely until they shall have received a further certificate of the secretary, assistant secretary, managing member,
general partner or equivalent of any such Person cancelling or amending the prior certificate of such Person.
(b) Information
Certificate. The Administrative Agent shall have received a fully completed Information Certificate in form and substance reasonably
satisfactory to the Administrative Agent, dated as of the Tranche 4 Borrowing Date, duly executed and delivered by a Responsible
Officer of the Borrower. All documents and agreements required to be appended to the Information Certificate, shall be in form
and substance reasonably satisfactory to the Administrative Agent and the Lenders, shall have been executed and delivered by the
requisite parties and shall be in full force and effect.
(c) Tranche
4 Borrowing Date Certificate. The following statements shall be true and correct, and the Administrative Agent shall have received
a certificate, dated as of the Tranche 4 Borrowing Date and in form and substance reasonably satisfactory to the Administrative
Agent (the “Tranche 4 Borrowing Date Certificate”), duly executed and delivered by a Responsible Officer
of the Borrower, certifying that: (i) both immediately before and after giving effect to the Borrowing on the Tranche 4 Borrowing
Date, (x) the representations and warranties set forth in each Loan Document that are qualified by materiality, Material Adverse
Effect or the like are, in each case, true and correct, (y) the representations and warranties set forth in each Loan Document
that are not qualified by materiality, Material Adverse Effect or the like are, in each case, true and correct in all material
respects, and (z) no Default has occurred and is continuing, or could reasonably be expected to result from the making of the Loans
being advanced, or the consummation of any Transactions contemplated to occur, on the Tranche 4 Borrowing Date, (ii) no Material
Adverse Change shall have occurred since December 31, 2018, and (iii) all of the conditions set forth in this Section 6.04 have
been satisfied (except to the extent waived in writing by the Administrative Agent). All documents and agreements required to be
appended to the Tranche 4 Borrowing Date Certificate, if any, shall be in form and substance reasonably satisfactory to the Administrative
Agent, shall have been executed and delivered by the requisite parties, and shall be in full force and effect.
(d) Delivery
of Notes. The Administrative Agent shall have received for each Lender a Note evidencing such Lender’s Tranche 4 Loan
duly executed and delivered by a Responsible Officer of the Borrower.
(e) Delivery
of Tranche 4 Warrant. The Administrative Agent shall have received fully executed counterparts of the Tranche 4 Warrant.
(f) Payoff
of Biotest Indebtedness. The Administrative Agent shall have received evidence reasonably satisfactory to it that substantially
simultaneously with the Borrowing of the Tranche 4 Loan, the Biotest Indebtedness, together with all accrued and unpaid interest
and fees, costs and expenses, shall have been indefeasibly paid in full, and the Administrative Agent shall have received executed
payoff letters, in form and substance reasonably satisfactory to the Administrative Agent, evidencing such indefeasible payment
in full of the Biotest Indebtedness, all documentation and obligations with respect to the Biotest Indebtedness shall have been
permanently terminated or cancelled, and all Liens, if any, securing the Biotest Indebtedness shall have been terminated and released.
(g) Opinions
of Counsel. The Administrative Agent shall have received one or more opinions, dated the Tranche 4 Borrowing Date and addressed
to the Administrative Agent and the Lenders, from independent legal counsel to the Borrower and the other Obligors, in form and
substance reasonably acceptable to the Administrative Agent.
(h) Fees,
Expenses, Etc. The Administrative Agent shall have received (i) for the account of each of the Lenders, each of the fees payable
pursuant to Section 3.D. of Amendment No. 2 and (ii) for its account and the account of each Lender, all other fees, costs and
expenses (including legal fees and expenses of Morrison & Foerster LLP) due and payable pursuant to Section 14.03.
G.
Schedule 1 to the Credit Agreement is hereby amended and restated in its entirety as Exhibit A hereto.
SECTION
2. ACKNOWLEDGEMENT,
AGREEMENT AND CONSENT AND REPRESENTATIONS AND WARRANTIES.
A.
Each Obligor confirms and agrees that, notwithstanding the effectiveness of this Amendment, the obligations of such
Obligor under each Loan Documents to which such Obligor is a party shall not be impaired and each Loan Document to which such Obligor
is a party is, and shall continue to be, in full force and effect and is hereby confirmed and ratified in all respects.
B.
Each Obligor hereby acknowledges and agrees that the Guaranteed Obligations will include all Obligations under, and
as defined in, the Credit Agreement as amended by this Amendment.
C.
Each Subsidiary Guarantor acknowledges and agrees that (i) notwithstanding the conditions to effectiveness set forth
in this Amendment, such Subsidiary Guarantor is not required by the terms of the Credit Agreement or any other Loan Document to
consent to the amendments to the Credit Agreement effected pursuant to this Amendment and (ii) nothing in the Credit Agreement,
this Amendment or any other Loan Document shall be deemed to require the consent of such Subsidiary Guarantor to any future amendments
to the Credit Agreement.
D.
In order to induce the Administrative Agent and the Lenders to enter into this Amendment, each Obligor represents and
warrants to the Administrative Agent and the Lenders that the following statements are true, correct and complete:
(i)
such Obligor has full power, authority and legal right to enter into this Amendment and each new Loan Document contemplated
hereby and to perform its obligations under this Amendment, the Credit Agreement as amended hereby, each such new Loan Document
and each existing Loan Document as amended hereby;
(ii)
the transactions contemplated by this Amendment are within such Obligor’s corporate powers and have been duly authorized
by all necessary corporate and, if required, by all necessary holders of Equity Interests. This Amendment, the Credit Agreement
and each other existing Loan Document as amended hereby, and each new Loan Document entered into and delivered pursuant hereto
or thereto has been duly executed and delivered by such Obligor and constitutes a legal, valid and binding obligation of such Obligor,
enforceable against such Obligor in accordance with its terms, except as such enforceability may be limited by (i) bankruptcy,
insolvency, reorganization, moratorium or similar laws of general applicability affecting the enforcement of creditors’ rights
and (ii) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding
in equity or at law);
(iii)
none of the transactions contemplated by this Amendment (1) requires any Governmental Approval of, registration or filing
with, or any other action by, any Governmental Authority or any other Person, except for such as have been obtained or made and
are in full force and effect, (2) will violate (x) any Law, (y) any Organic Document of any Obligor or any of its Subsidiaries
or (z) any order of any Governmental Authority,, (3) will violate or result in a default under any Material Agreement binding upon
any Obligor or any of its Subsidiaries that, individually or in the aggregate, could reasonably be expected to result in a Material
Adverse Effect or (4) will result in the creation or imposition of any Lien (other than Permitted Liens) on any asset of such Obligor
or any of its Subsidiaries; and
(iv) both
immediately before and after giving effect to this Amendment, (x) the representations and warranties set forth in this Amendment
and each other Loan Document (including the Credit Agreement as amended hereby and each new Loan Document entered into in connection
herewith) that are qualified by materiality, Material Adverse Effect or the like shall, in each case, be true and correct, (y)
the representations and warranties set forth in this Amendment and each other such Loan Document that are not qualified by materiality,
Material Adverse Effect or the like shall, in each case, be true and correct in all material respects and (z) no Default shall
have then occurred and be continuing, or would result from this Amendment or the transaction contemplated hereby.
SECTION
3. CONDITIONS
TO EFFECTIVENESS. This Amendment shall become effective only upon the satisfaction of the following conditions precedent (the
date of satisfaction of such conditions being referred to as the “Amendment Effective Date”):
A.
The Obligors, the Administrative Agent and the Lenders shall have indicated their consent to this Amendment by the execution
and delivery of the signature pages hereto to the Administrative Agent.
B.
The Tranche 4 Borrowing Date shall have occurred and all conditions precedent thereto (as set forth in the Credit Agreement,
as amended hereby) shall have been satisfied.
C.
The Lenders shall have received (i) an officer’s certificate of each Obligor, either confirming that (x) there
have been no changes to its Organic Documents since the Amendment No. 1 Effective Date, or if there have been changes to its Organic
Documents since such date, certifying as to such changes and providing copies of its Organic Documents as in effect on the Amendment
Effective Date, and (y) (1) the representations and warranties set forth in this Amendment and each other Loan Document (including
the Credit Agreement both immediately before and after giving effect to this Amendment and each new Loan Document required to be
delivered in connection herewith) that are qualified by materiality, Material Adverse Effect or the like are, in each case, true
and correct, (2) the representations and warranties set forth in this Amendment and each other such Loan Document (including the
Credit Agreement both immediately before and after giving effect to this Amendment and each new Loan Document required to be delivered
in connection herewith) that are not qualified by materiality, Material Adverse Effect or the like are, in each case, true and
correct in all material respects and (3) no Default has occurred and is continuing, or would result from this Amendment or the
transaction contemplated hereby, (ii) copies of resolutions of each Obligor’s Board then in full force and effect authorizing
the execution, delivery and performance of this Amendment certified by a Responsible Officer of such Obligor, (iii) a copy of a
good standing certificate of each Obligor dated a date reasonably close to the Amendment Effective Date, and (iv) an incumbency
certificate from each Obligor.
D.
The Administrative Agent shall have received (i) for the account of each of the Lenders, a delayed draw fee in the amount
equal to (x) the original principal amount of the Tranche 4 Loan made on the Tranche 4 Borrowing Date multiplied by (y) 1.0%, (ii)
for the account of the Lenders, an amendment fee in an amount equal to $637,500 and (iii) all other fees, costs and expenses (including
legal fees and expenses of Morrison & Foerster LLP) due and payable pursuant to Section 14.03 of the Credit Agreement (as amended
hereby).
SECTION
4. MISCELLANEOUS
A.
Reference to and Effect on the Loan Documents.
(i) On
and after the Amendment Effective Date, each reference in the Credit Agreement or any Loan Document (other than this Amendment)
to the “Credit Agreement” shall mean and be a reference to the Credit Agreement as amended by this Amendment.
(ii)
Except as expressly amended by this Amendment, all of the representations, warranties, terms, covenants, conditions and
other provisions of the Loan Documents shall remain unchanged and shall continue to be, and shall remain, in full force and effect
in accordance with their respective terms. The amendments, consents and modifications set forth herein shall be limited precisely
as provided for herein to the provisions expressly amended herein or otherwise modified or consented to hereby and shall not be
deemed to be an amendment to, waiver of, consent to or modification of any other term or provision of the Credit Agreement or any
other Loan Document or of any transaction or further or future action on the part of any Obligor which would require the consent
of the Lenders or the Administrative Agent under the Credit Agreement or any other Loan Document.
(iii)
The execution, delivery and performance of this Amendment shall not constitute a waiver of any provision of, or operate
as a waiver of any right, power or remedy of the Administrative Agent or any Lender under any Loan Document or applicable Law.
(iv)
This Amendment shall constitute a Loan Document.
B.
Captions. The captions and section headings appearing herein are included solely for convenience of reference and are
not intended to affect the interpretation of any provision of this Amendment.
C.
Governing Law. This Amendment and the rights and obligations of the parties hereunder shall be governed by, and construed
in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the
application of the laws of any other jurisdiction; provided that Section 5-1401 of the New York General Obligations Law
shall apply.
D.
Counterparts. This Amendment may be executed in any number of counterparts, all of which taken together shall constitute
one and the same instrument and any of the parties hereto may execute this Amendment by signing any such counterpart. Delivery
of an executed signature page of this Amendment by facsimile transmission or electronic transmission (in PDF format) shall be effective
as delivery of a manually executed counterpart hereof.
[Signature Pages Follow]
IN WITNESS WHEREOF,
the parties hereto have caused this Amendment to be duly executed and delivered by their respective officers thereunto duly authorized
as of the date first written above.
|
|
BORROWER:
|
|
|
|
|
|
|
ADMA BIOLOGICS, INC.
|
|
|
|
|
|
|
By
|
/s/ Brian Lenz
|
|
|
|
Name: Brian Lenz
|
|
|
|
Title: Executive Vice President, Chief Financial Officer and Secretary
|
|
|
|
|
|
|
|
|
|
|
SUBSIDIARY GUARANTORS:
|
|
|
|
|
|
|
ADMA BIOCENTERS GEORGIA INC.
|
|
|
|
|
|
|
By
|
/s/ Brian Lenz
|
|
|
|
Name: Brian Lenz
|
|
|
|
Title: Vice President and Chief Financial Officer
|
|
|
|
|
|
|
ADMA BIOMANUFACTURING, LLC
|
|
|
|
|
|
|
By
|
/s/ Brian Lenz
|
|
|
|
Name: Brian Lenz
|
|
|
|
Title: Vice President and Chief Financial Officer
|
|
|
|
|
|
|
ADMA PLASMA BIOLOGICS, INC.
|
|
|
|
|
|
|
By
|
/s/ Brian Lenz
|
|
|
|
Name: Brian Lenz
|
|
|
|
Title: Vice President and Chief Financial Officer
|
PERCEPTIVE CREDIT HOLDINGS II, LP, as
Administrative
Agent and Lender
By Perceptive Credit Opportunities GP, LLC,
its
general partner
|
By:
|
/s/ Sandeep Dixit
|
|
|
|
Name: Sandeep Dixit
|
|
|
|
Title: Chief Credit Officer
|
|
|
|
|
|
|
By:
|
/s/ Sam Chawla
|
|
|
|
Name: Sam Chawla
|
|
|
|
Title: Portfolio Manager
|
|
Exhibit
A
Schedule
1
to Credit Agreement
Commitments
|
Lender
|
Commitment
|
Proportionate Share
|
|
Perceptive Credit Holdings II, LP
|
$100,000,000
|
100%
|
|
TOTAL
|
$100,000,000
|
100%
|
ADMA Biologics Enters Into $100 Million
Credit Facility Loan Amendment with Perceptive Advisors
Increases Size of Facility and Extends
Interest-Only Period Enabling ADMA to Reach Profitability Prior to Maturity
Demonstrates Perceptive’s Commitment
and Long-Term Positive Outlook for ADMA’s Commercial IG Drug Product Portfolio, IP Estate, and Asset Value Supported by Plasma
Centers and a Vertically Integrated Plasma Fractionation and Fill/Finish Manufacturing Plant
RAMSEY, N.J. and BOCA RATON, FL., – December 9, 2020
– ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical
company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced an amendment to
its existing senior secured term loan with Perceptive Advisors (“Perceptive”), which provides for an additional loan
tranche of $15 million, increasing the total size of the credit facility to $100 million. The amended terms for the existing $85
million credit facility additionally provide for, among other things, a two-year extension of the interest only period through
the duration of the credit facility now maturing in March 2024, at an unchanged borrowing rate of 11%. The newly issued loan tranche
of $15 million from Perceptive was fully drawn and used to pay the remaining obligations under the Biotest AG subordinated note
entered into in June of 2017, at a 7% mutually agreed discount with no associated prepayment penalties. This additional loan tranche
carries the same terms as the amended senior secured loans. There were no modifications made to the existing revenue covenants
of the credit facility with Perceptive.
“This upsized loan amendment demonstrates Perceptive’s
long-term view for the plasma industry and ADMA’s important role as a reliable producer of plasma-derived biologics,”
said Joseph Edelman, Chief Executive Officer and Founder of Perceptive Advisors. “We remain committed to supporting ADMA’s
business and unlocking shareholder value that we believe has yet to be realized. We are optimistic that the asset value of manufactured
plasma and plasma collection centers will continue to appreciate into the future.”
“This amendment
to our senior secured term loan, with its increased size and extended maturities, strengthens our long-term capital position and
allows us to continue to execute on our strategic priorities, including supply chain enhancement initiatives and plasma center
expansion, in addition to generating considerable near-term and ongoing revenue growth,” stated Adam Grossman, President
and Chief Executive Officer of ADMA. “Despite ongoing COVID-19 headwinds, we remain
on track to achieve our previously provided guidance for topline revenues of $250 million or greater by 2024, and we are confident
that we are well-positioned to achieve profitability prior to the new 2024 maturity date of the loan. The continued support from
Perceptive, who remains our largest equity holder, is a testament to the shareholder value that we believe will be created as we
execute on these corporate objectives and establish ADMA as the only fully integrated American plasma fractionator.”
“Perceptive is pleased to provide additional capital to
support ADMA’s near-term revenue and profitability growth strategy,” stated Sam Chawla, Portfolio Manager at Perceptive.
“The Company has made significant progress and has met all of our goals and objectives to date. We look forward to seeing
ADMA’s continued progress and supporting the Company’s mission and value creating business objectives, focused on improving
healthcare options for patients at risk of infectious diseases.”
The Perceptive credit amendment has an interest-only term with
a maturity date of March 1, 2024. Borrowings under the Perceptive credit agreement bear interest at a rate per annum equal to 7.5%
plus the greater of one-month LIBOR and 3.5%. ADMA will also issue a warrant to Perceptive to purchase 2,390,000 shares of the
Company’s common stock at the lower of ADMA’s closing share price on the date of the amendment and the 10-day VWAP
ahead of closing.
The debt financing disclosed in this press release is not all
inclusive and, as such, the statements in this press release are qualified in their entirety by reference to the description of
the debt financing transaction and corresponding exhibits, which are included in a Current Report on Form 8-K filed concurrently
with this press release by ADMA with the Securities and Exchange Commission.
About Perceptive Advisors (Perceptive)
Founded in 1999, Perceptive Advisors
is a leading healthcare focused investment firm with over $8.5 billion of regulatory assets under management as of October 29,
2020. Since inception, Perceptive Advisors has focused on supporting progress in the life sciences industry by identifying opportunities
and directing financial resources toward the most promising technologies in modern healthcare. For more information about
Perceptive, visit www.perceptivelife.com.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is an end-to-end American commercial
biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the
treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA
currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics
for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin
intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous,
human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide
enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma
fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also
operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the
manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human
immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and
management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune
compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and
10,259,865 related to certain aspects of its products and product candidates. For more information, please visit
www.admabiologics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements”
pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,”
“our” or the “Company”). Forward-looking statements include, without limitation, any statement that may
predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “estimate,”
“project,” “intend,” “forecast,” “target,” “anticipate,” “plan,”
“planning,” “expect,” “believe,” “will,” “should,” “could,”
“would,” “may,” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking
statements also include, but are not limited to, statements about ADMA’s future results of operations; timing of revenue
and profitability; execution of corporate objectives and achievement of goals; realization of shareholder value; and future appreciation
of the asset value of manufactured plasma and plasma collection centers. Actual events or results may differ materially from those
described in this document due to a number of important factors. Current and prospective security holders are cautioned that there
also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to
the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements
or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties
and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results
expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in
our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and
any amendments thereto.
COMPANY
CONTACT:
Skyler Bloom
Director, Investor Relations and Corporate
Strategy | 201-478-5552 | sbloom@admabio.com
INVESTOR RELATIONS CONTACT:
Sam Martin
Managing Director, Argot Partners | 212-600-1902
| sam@argotpartners.com